Teva Pharmaceutical Industries (TEVA) stock plummeted over 11% in intraday trading on Wednesday, following the company's disappointing fourth-quarter earnings results and a gloomy outlook for 2025.
The Israeli pharmaceutical giant reported a significant decline in its Q4 non-GAAP earnings per share and revenue compared to the same period last year. TEVA's non-GAAP EPS for the quarter stood at $0.71, down from $1.00 a year earlier, while its revenue fell to $4.23 billion from $4.46 billion. Although the EPS met analysts' expectations, the revenue missed their forecast of $4.15 billion.
Moreover, TEVA's guidance for the full year 2025 fell short of analysts' projections. The company expects its 2025 non-GAAP diluted EPS to be in the range of $2.35 to $2.65 on revenue of $16.8 billion to $17.4 billion. Analysts had forecasted a non-GAAP EPS of $2.96 on revenue of $17.09 billion.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。